News for Rhythm Pharmaceuticals, Inc. (RYTM.MX)

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( RYTM), a global commercial-stage biopharmaceutical company focused on transforming t

- **Rhythm Pharmaceuticals (RYTM) sees a 17.1% surge as the Nasdaq Index rebounds.** - **Analysts predict a substantial 41.9% earnings growth this year for RYTM

U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday. Shares of Marvell Technology, Inc. MRVL rose sharply during Tuesday's s...

Key Highlights: Rhythm Pharmaceuticals' setmelanotide shows promising results in Phase 3 trial for hypothalamic obesity. Analysts foresee a potential ups

**media[587682]**

Company to host conference call on April 7 at 8 a.m. ETBOSTON, April 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commer

Rhythm Pharmaceuticals Inc (RYTM), a Boston-based biopharmaceutical company, announced on March 20, 2025, that it has reacquired the rights to its drug IMCIVREE

Transaction Overview On March 6, 2025, RA Capital Management, L.P. made a significant addition to its portfolio by acquiring 1,605,725 shares of Janux Therapeut

Recent Acquisition by RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) On March 13, 2025, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) made a significant move

BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( RYTM), a global commercial-stage biopharmaceutical company focused on transforming t

BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. ( RYTM), a global commercial-stage biopharmaceutical company focused on transforming t

New registry study to focus on impact of fatigue in people with craniopharyngioma BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (

Strengths: Innovative therapies and strong market presence in rare disease treatment.Weaknesses: Limited operating history and ongoing net losses.Opportunities

Significant Transaction by PERCEPTIVE ADVISORS LLC (Trades, Portfolio) On January 8, 2025, PERCEPTIVE ADVISORS LLC (Trades, Portfolio) executed a noteworthy tra

Cash and Cash Equivalents: $320.6 million at the end of 2024.Revenue: $41.8 million in Q4 2024; $130.1 million for the full year 2024.Cost of Sales: $3.8 milli

Feb 26, 2025 / 01:00PM GMTOperator Good day and welcome to Rhythm Pharmaceuticals fourth quarter and fiscal year 2024 earnings conference call. [Operator Instru

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ETCompany ParticipantsDavid Connolly – Investor...

The following slide deck was published by Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals (RYTM) delivered earnings and revenue surprises of -4.35% and 2.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?